A recently published evidence-based guideline for managing patients with primary ER-positive HER2-neg breast cancer clearly supported the use of ER and PR expression levels at diagnosis for triaging patients into three groups for the expected benefit of NET. The gene discussed is ERBB2; the disease is breast cancer.